Drug Profile
Research programme: cancer diagnostics and therapeutics - Bayer/German Cancer Research Center
Alternative Names: Cancer immunotherapies - Bayer/German Cancer Research CenterLatest Information Update: 30 Dec 2022
Price :
$50
*
At a glance
- Originator Bayer; German Cancer Research Center
- Class Antineoplastics; Diagnostic agents; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 30 Dec 2022 Discontinued - Preclinical for Cancer (Diagnosis) in Germany (unspecified route)
- 30 Dec 2022 Discontinued - Preclinical for Cancer in Germany (unspecified route)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Cancer in Germany